Patient Guide: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 44 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06036836
Status: ACTIVE_NOT_RECRUITING
Condition: Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Phase: PHASE2

Where You Can Participate

This study is available at 44 locations across the country.

Top locations include:
  • • New Haven, Connecticut
  • • Boston, Massachusetts
  • • New Brunswick, New Jersey
  • • And 41 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) - Join Clinical Trial NCTNCT06036836

How to Join This Clinical Trial - NCTNCT06036836

Learn how to participate in this PHASE2 trial studying an investigational therapy for Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT06036836 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 44 locations. Find a study site near you:

Clinical Research Site

New Haven, Connecticut 06510 - United States

Status: Contact for availability

Clinical Research Site

Boston, Massachusetts 02215 - United States

Status: Contact for availability

Clinical Research Site

New Brunswick, New Jersey 08903 - United States

Status: Contact for availability

Clinical Research Site

Durham, North Carolina 27710 - United States

Status: Contact for availability

Clinical Research Site

Cleveland, Ohio 44195 - United States

Status: Contact for availability

Clinical Research Site

Bethlehem, Pennsylvania 18015 - United States

Status: Contact for availability

Clinical Research Site

Pittsburgh, Pennsylvania 15232 - United States

Status: Contact for availability

Clinical Research Site

Dallas, Texas 75390-9179 - United States

Status: Contact for availability

Clinical Research Site

Darlinghurst, New South Wales 2010 - Australia

Status: Contact for availability

Clinical Research Site

St Leonards, New South Wales 2065 - Australia

Status: Contact for availability

And 34 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships